TrialGynecologic oncology2023

A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer.

Sileny N Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.